Drug recall · December 16, 2015
Norpace CR recall
Why: Failed Dissolution Specification
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.
- Lots / codes
Lot #: C150065; C150064, Exp 6/16
- Quantity
- a) 4005 bottles, b) 104 bottles
- Company
- Pfizer Inc., New York, NY
- Distribution
- Nationwide
- Initiated
- December 2, 2015 · Voluntary: Firm initiated
- Classified
- December 10, 2015
- Reported
- December 16, 2015
- Ended
- July 26, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Disopyramide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.